Literature DB >> 27388591

Hyperglycemia in pasireotide-treated patients with acromegaly and its treatment.

Anton Luger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27388591     DOI： 10.1007/s12020-016-1029-z

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  11 in total

1.  Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients.

Authors:  Michael Madsen; Per L Poulsen; Hans Orskov; Niels Møller; Jens O L Jørgensen
Journal:  J Clin Endocrinol Metab       Date:  2011-06-01       Impact factor: 5.958

Review 2.  Opportunities in somatostatin research: biological, chemical and therapeutic aspects.

Authors:  Gisbert Weckbecker; Ian Lewis; Rainer Albert; Herbert A Schmid; Daniel Hoyer; Christian Bruns
Journal:  Nat Rev Drug Discov       Date:  2003-12       Impact factor: 84.694

Review 3.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

4.  Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.

Authors:  Mônica R Gadelha; Marcello D Bronstein; Thierry Brue; Mihail Coculescu; Maria Fleseriu; Mirtha Guitelman; Vyacheslav Pronin; Gérald Raverot; Ilan Shimon; Kayo Kodama Lievre; Juergen Fleck; Mounir Aout; Alberto M Pedroncelli; Annamaria Colao
Journal:  Lancet Diabetes Endocrinol       Date:  2014-09-24       Impact factor: 32.069

5.  SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.

Authors:  C Bruns; I Lewis; U Briner; G Meno-Tetang; G Weckbecker
Journal:  Eur J Endocrinol       Date:  2002-05       Impact factor: 6.664

6.  Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues.

Authors:  Marinella Tzanela; Dimitra A Vassiliadi; Nikolaos Gavalas; Andrea Szabo; Eleni Margelou; Athina Valatsou; Charalambos Vassilopoulos
Journal:  Clin Endocrinol (Oxf)       Date:  2011-07       Impact factor: 3.478

7.  Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.

Authors:  Ariel L Barkan; Pia Burman; David R Clemmons; William M Drake; Robert F Gagel; Philip E Harris; Peter J Trainer; Aart Jan van der Lely; Mary Lee Vance
Journal:  J Clin Endocrinol Metab       Date:  2005-08-02       Impact factor: 5.958

8.  Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.

Authors:  Astrid Breitschaft; Ke Hu; Karina Hermosillo Reséndiz; Christelle Darstein; Georg Golor
Journal:  Diabetes Res Clin Pract       Date:  2013-12-25       Impact factor: 5.602

9.  Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.

Authors:  Laura De Marinis; Antonio Bianchi; Alessandra Fusco; Vincenzo Cimino; Marilda Mormando; Laura Tilaro; Gherardo Mazziotti; Alfredo Pontecorvi; Andrea Giustina
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

10.  Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.

Authors:  Herbert A Schmid; Thierry Brue; Annamaria Colao; Mônica R Gadelha; Ilan Shimon; Karen Kapur; Alberto M Pedroncelli; Maria Fleseriu
Journal:  Endocrine       Date:  2016-02-23       Impact factor: 3.633
View more
  4 in total

1.  Long non-coding RNA Hottip modulates high-glucose-induced inflammation and ECM accumulation through miR-455-3p/WNT2B in mouse mesangial cells.

Authors:  Xiang-Jun Zhu; Zhaung Gong; Shu-Juan Li; Hai-Ping Jia; Da-Lin Li
Journal:  Int J Clin Exp Pathol       Date:  2019-07-01

Review 2.  The Interaction of Insulin and Pituitary Hormone Syndromes.

Authors:  Marie Helene Schernthaner-Reiter; Peter Wolf; Greisa Vila; Anton Luger
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-28       Impact factor: 5.555

3.  Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study.

Authors:  Maria Fleseriu; Elisha Rusch; Eliza B Geer
Journal:  Endocrine       Date:  2016-11-28       Impact factor: 3.633

4.  Approach to the Patient With Treatment-resistant Acromegaly.

Authors:  Eva C Coopmans; Aart J van der Lely; Sebastian J C M M Neggers
Journal:  J Clin Endocrinol Metab       Date:  2022-05-17       Impact factor: 6.134
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.